What this means
This study plans to track aging-like changes in immune cells as patients get chemotherapy before surgery. It has not started recruiting, so no results exist yet.
Plain-English summary written by an AI model from the registry listing.
- Status
- Opening soon
- Who can join
- Ages 18–40
- Where
- Not listed
The science
- Registered title
- Studying the Senescent T Cell Features and Its Relationship with the Chemotherapy Efficacy in Young TNBC
- Trial ID
- NCT06684054 ↗
- Phase
- Not applicable
- Study type
- observational
- Conditions
- T-Cell Dysfunction, Chemotherapy Effect, Adverse Events
- What is tested
- docetaxel, anthracycline, cyclophosphamide
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
- Ages
- 18 Years to 40 Years
- Dates
- First posted Nov 12, 2024 · updated Nov 12, 2024
Registry summary
The goal of this observational study is to learn about the features of senescent T lymphocytes induced by chemotherapy and its relationship with the efficacy of neoadjuvant chemotherapy in young triple-negative breast cancer (TNBC) patients.
The main questions it aims to answer are:
- What are the senescent features of peripheral T lymphocytes in young TNBC patients receiving neoadjuvant chemotherapy and the relationship with the efficacy of neoadjuvant chemotherapy?
- What is the relationship between senescent T cells and adverse events, DFS and tumor infiltrating lymphocytes?
- Participants will receive 6 cycles of docetaxel + adriamycin/epirubicin + cyclophosphamide (TEC/TAC) neoadjuvant chemotherapy, and radical mastectomy after chemotherapy.
2.5ml peripheral venous blood will be collected before chemotherapy, after 2 cycles of chemotherapy, before surgery, and six months after surgery.
3.Clinicopathological data, chemotherapy-related adverse events and prognostic information of patients should be collected during the study.